EGFR and non-small cell lung carcinoma: Therefore, we conducted a meta-analysis of patients with resected EGFR-mutant NSCLC treated with adjuvant EGFR-TKIs versus chemotherapy or a placebo to address the questions relating to the application of adjuvant EGFR-TKIs in NSCLC patients.